Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volixibat potassium phase 2 study in adults with nonalcoholic steatohepatitis
2016-000203-82Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Volixibat potassium with Placebo (2 arms). Primary endpoint: Histologic response at Week 48. Started May 2016; status: completed.
02
Drugs
volixibat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-000203-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000203-82.